Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 10/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.60 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.60 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | IKBKB | O14920 | 1/20 | 0.60 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | MYLK | Q15746 | 1/20 | 0.60 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL130511 | 0.95 | TMPRSS4 (0.65) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL16707262 | 0.88 | TMPRSS4 (0.61) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL330156 | 0.87 | NR1H4 (0.60) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL16707257 | 0.87 | TMPRSS4 (0.60) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL4498846 | 0.86 | TMPRSS4 (0.62) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL16707255 | 0.86 | TMPRSS4 (0.59) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL3497425 | 0.85 | TMPRSS4 (0.64) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL10282820 | 0.85 | P2RX1 (0.57) | TMPRSS4P2RX1P2RX4P2RX7CYP1A2 | |
| SCHEMBL16707256 | 0.85 | TMPRSS4 (0.58) | TMPRSS4P2RX1P2RX4P2RX7MEN1 | |
| SCHEMBL3281999 | 0.84 | RHOC (0.56) | TMPRSS4P2RX1P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160346302-A1 | NOVEL METHODS | AEROMICS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20150133405-A1 | Methods | AEROMICS, INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346302-A1 | NOVEL METHODS | AQP4, AQP1, AQP3 | TMPRSS4 2227/4885P2RX1 400/4885P2RX4 210/4885 |
| US-20150133405-A1 | Methods | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885P2RX1 2910/4885P2RX4 2498/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885P2RX1 3317/4885P2RX4 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.